Eptifibatide (Monograph)

Brand name: Integrilin
Drug class: Platelet-aggregation Inhibitors
- Antithrombotic Agents
- Platelet-aggregation Inhibitors
- GP IIb/IIIa Receptor Inhibitors
Chemical name: Cyclic(1-6)-disulfide-N6amidino-N2-(3-mercaptopropionyl)-l-lysylglycyl-l-α-aspartyl-l-tryptophyl-l-prolyl-l-cysteinamide
Molecular formula: C₃₅H₄₉N₁₁O₉S₂
CAS number: 148031-34-9

Medically reviewed by Drugs.com on Sep 9, 2024. Written by ASHP.

Introduction

Platelet-aggregation inhibitor;¹ ² ³ ¹⁰ ¹¹ ⁷¹ a platelet glycoprotein (GP IIb/IIIa)-receptor inhibitor.² ⁶ ⁷ ¹¹ ¹⁴ ²⁶ ³⁷ ⁴⁴ ⁴⁸ ⁵⁰

Uses for Eptifibatide

Non-ST-Segment-Elevation Acute Coronary Syndromes

Adjunct to anticoagulant therapy (e.g., heparin [referring throughout this monograph to unfractionated heparin], low molecular weight heparin [LMWH]), aspirin, and a P2Y12 platelet adenosine diphosphate (ADP)-receptor antagonist (e.g., clopidogrel, prasugrel, ticagrelor) to reduce risk of acute cardiac ischemic events (death and/or MI) in patients with non-ST-segment-elevation acute coronary syndromes (NSTE ACS) (i.e., unstable angina or non-ST-segment-elevation MI [NSTEMI]) who are managed medically or with PCI.¹ ⁴ ⁸ ⁴⁰ ⁷² ¹¹³ ⁹⁹⁴ ⁹⁹⁵ ¹¹⁰⁰

Adjunctive therapy with a GP IIb/IIIa-receptor inhibitor can reduce the incidence of cardiac ischemic events, including subsequent MI and death, in patients with NSTE ACS.¹⁶ ⁴⁰ ⁴³ ⁴⁹ ⁵² ⁵⁶

The American College of Cardiology Foundation (ACCF) and AHA recommend either clopidogrel or IV administration of a GP IIb/IIIa-receptor inhibitor in addition to aspirin therapy prior to diagnostic angiography (“upstream”) in patients in whom an initial invasive management strategy is planned; eptifibatide or tirofiban is the preferred GP IIb/IIIa inhibitor for this use.⁹⁹¹ Abciximab is recommended only if there is no appreciable delay before angiography and PCI is likely to be performed.⁹⁹¹

The American College of Chest Physicians (ACCP) states that a clear risk-benefit profile has not been established for use of GP IIb/IIIa-receptor inhibitors in patients with ACS who are not routinely scheduled for early revascularization.¹⁰¹⁶

Eptifibatide and tirofiban not recommended by AHA in women with NSTE ACS who are at lower risk for adverse cardiac events and are managed with a conservative strategy, because of little demonstrated benefit and possible detrimental effects.¹²⁸

Acute Ischemic Complications of PCI

Adjunct to anticoagulant therapy (heparin, LMWH), aspirin, and a P2Y12-receptor antagonist (e.g., clopidogrel, prasugrel, ticagrelor) to reduce risk of acute ischemic complications (death, MI, and/or need for urgent revascularization procedures) in patients undergoing PCI, including coronary artery stenting.¹ ⁴ ⁸ ¹⁰ ¹¹ ¹⁶ ⁴³ ⁹⁹⁴ ⁹⁹⁵

ACCF, AHA, the Society for Cardiovascular Angiography and Interventions (SCAI), and other experts currently do not recommend routine use of GP IIb/IIIa-receptor inhibitors in patients with ST-segment-elevation MI (STEMI) undergoing PCI; however, selective use of these drugs as an adjunct to heparin may be reasonable in certain high-risk patients (e.g., those with large anterior MI and/or large thrombus).⁹⁹⁴ ¹⁰¹⁶

ACCF/AHA/SCAI state that administration of a GP IIb/IIIa-receptor inhibitor at the time of PCI as an adjunct to heparin may be particularly useful in patients with NSTE ACS who have high-risk features (e.g., elevated troponin) and are not receiving bivalirudin and are not adequately pretreated with clopidogrel.⁹⁹⁴

Regarding choice of GP IIb/IIIa-receptor inhibitor in patients undergoing PCI, IV abciximab, “double-bolus” IV eptifibatide, and high-dose tirofiban by direct IV injection all produce a high degree of platelet inhibition and reduce ischemic complications.⁹⁹⁴

Adjunctive Therapy During Thrombolysis to Prevent Reocclusion

Has been used as an adjunct to thrombolytic therapy (e.g., alteplase, tenecteplase) in a limited number of patients to prevent coronary artery reocclusion^{† [off-label]} following acute MI.⁶ ⁸ ¹³ ¹⁴ ³⁴ ⁴³

Eptifibatide Dosage and Administration

General

In patients with NSTE ACS, administer as soon as possible following diagnosis.¹ ⁸ ⁷²
Discontinue prior to CABG.¹

Adjunctive Antithrombotic Therapy: General Considerations

Used in conjunction with aspirin and heparin in clinical studies.¹ ⁴ ⁸ ¹⁰ ¹² ¹³ ¹⁴ ¹⁹ ⁴⁰
Dosage of heparin required to maintain an appropriate activated clotting time (ACT) during concomitant therapy with eptifibatide may be lower than with heparin monotherapy.¹⁹ ⁷² ¹¹³ ⁹⁹⁴ (See Specific Drugs under Interactions.)
Caution when used in patients requiring thrombolytic therapy.¹ (See Specific Drugs under Interactions.)

Adjunctive Antithrombotic Therapy When Used in Management of NSTE ACS

Aspirin: Manufacturer recommends 160–325 mg initially and daily thereafter.¹
Heparin sodium during medical management: In patients weighing ≥70 kg, 5000 units (IV loading dose) followed by continuous IV infusion of 1000 units/hour.¹ In patients weighing <70 kg, 60 units/kg followed by continuous IV infusion of 12 units/kg per hour.¹ Adjust dose to maintain a target aPTT of 50–70 seconds.¹ (See Laboratory Monitoring under Cautions.)
Heparin sodium in patients undergoing PCI: Administer multiple IV injections of heparin based on ACT determinations during PCI to achieve and maintain an ACT of ≥200 seconds.¹ ¹¹⁷ ¹¹⁸

Adjunctive Antithrombotic Therapy When Used to Reduce Risk of Acute Ischemic Complications of PCI

Aspirin: Manufacturer recommends 160–325 mg 1–24 hours prior to PCI and daily thereafter.¹ ACCF/AHA/SCAI recommends that aspirin 325 mg be given prior to PCI in patients not already receiving maintenance aspirin therapy.⁹⁹⁴ Patients already receiving maintenance aspirin therapy should receive a dose of 81–325 mg before the procedure.⁹⁹⁴
P2Y12-receptor antagonist: A loading dose of clopidogrel, prasugrel, or ticagrelor also is recommended prior to PCI in patients undergoing stent placement.⁹⁹⁴ ⁹⁹⁵
Heparin: 50–70 units/kg 6 hours prior to PCI (target ACT of ≥200 seconds).¹ Administer additional injections during PCI to maintain an ACT of 200–300 seconds.¹ (See Laboratory Monitoring under Cautions.) Consider a lower dosage of heparin in women and geriatric patients receiving a GP IIb/IIIa-receptor inhibitor to decrease the increased risk of minor bleeding.¹²⁸ Postprocedural use of heparin not recommended.¹ ¹⁰ ²⁶

Administration

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Administer by IV injection followed by IV infusion using a controlled-infusion device (e.g., pump).¹

For IV injection, withdraw appropriate dose from the 10-mL vial and administer undiluted.¹ ⁷¹

For continuous IV infusion, spike the 100-mL vial with a vented infusion set; center spike within the circle on stopper top.¹ Administer solution directly from vial.¹ ⁸ ⁷¹

Discard unused portion.¹

Dilution

Administer undiluted.¹

Rate of Administration

For IV injection, administer over 1–2 minutes.¹ ⁷¹

Dosage

Adults

NSTE ACS

IV

180 mcg/kg by IV injection as soon as possible following diagnosis, followed by IV infusion of 2 mcg/kg per minute until hospital discharge or initiation of CABG, or for ≤72 hours.¹ ⁸ ⁷²

If patient undergoes PCI while receiving eptifibatide, continue infusion (at 2 mcg/kg per minute) until hospital discharge or for ≤18–24 hours after procedure, whichever comes first, up to a maximum of 96 hours.¹

Acute Ischemic Complications of PCI

IV

180 mcg/kg by IV injection immediately before initiation of PCI, immediately followed by IV infusion of 2 mcg/kg per minute and a second IV injection of 180 mcg/kg 10 minutes after the first IV injection.¹ ¹¹⁷ ¹¹⁸

Continue infusion (at 2 mcg/kg per minute) until hospital discharge or for ≤18–24 hours, whichever comes first.¹ A minimum infusion period of 12 hours is recommended.¹

Prescribing Limits

Adults

NSTE ACS

IV

Maximum IV infusion of 72 hours.¹ ⁸ ⁷²

In patients undergoing PCI, maximum IV infusion of 96 hours.¹

Special Populations

Hepatic Impairment

No specific dosage recommendations at this time.⁸

Renal Impairment

NSTE ACS

No dosage adjustment required in patients with mild to moderate renal impairment (Cl_cr ≥50 mL/minute).¹

In patients with Cl_cr <50 mL/minute, 180 mcg/kg by IV injection as soon as possible following diagnosis, followed by IV infusion of 1 mcg/kg per minute.¹

Acute Ischemic Complications of PCI

In patients with Cl_cr <50 mL/minute, 180 mcg/kg by IV injection immediately before initiation of PCI, followed by IV infusion of 1 mcg/kg per minute and a second IV injection of 180 mcg/kg 10 minutes after the first IV injection.¹

Geriatric Patients

No dosage adjustment was made for geriatric patients in clinical trials.¹ (See Geriatric Use under Cautions.)

Cautions for Eptifibatide

Contraindications

History of bleeding diathesis¹ ¹⁰ ¹³ or active abnormal bleeding within previous 30 days.¹ ¹⁰ ¹² ¹³
Severe uncontrolled hypertension (SBP >200 mm Hg or DBP >110 mm Hg with antihypertensive therapy).¹ ¹⁰ ¹³
Recent (within 6 weeks) major surgery.¹ ¹⁰ ¹² ¹³
History of stroke within 30 days or any history of hemorrhagic stroke.¹ ¹⁰ ¹² ¹³
Current or planned therapy with another GP IIb/IIIa-receptor inhibitor.¹
Patients undergoing renal dialysis.¹
Known hypersensitivity to eptifibatide or any ingredient in the formulation.¹

Warnings/Precautions

Warnings

Bleeding

Risk of major bleeding (e.g., intracranial hemorrhage, GU or GI bleeding, bleeding at femoral vascular access site)¹ ⁸ ¹⁷ ⁷¹ ⁸⁵ ¹¹⁷ and minor bleeding (e.g., spontaneous gross hematuria, spontaneous hematemesis);¹ ⁸ ¹⁷ ⁷² ⁸⁵ may require blood or platelet transfusions.¹ ¹⁰ ¹¹⁷ (See Bleeding Precautions and see Laboratory Monitoring under Cautions.) Patients weighing <70 kg at increased risk of major bleeding.¹

If bleeding cannot be controlled by pressure, discontinue eptifibatide and concomitant heparin immediately.¹

Use not recommended in patients with hematocrit <30%.⁸ ⁷²

Thrombocytopenia

Thrombocytopenia reported.¹¹⁰ ¹¹¹ Severe thrombocytopenia (platelet count <20,000/mm³) reported less frequently than with abciximab.⁸ ²⁶ ⁴⁰ ⁵⁵ ⁷² ⁹³ ⁹⁹ ¹¹¹

Determine platelet counts prior to treatment and periodically (e.g., daily)⁷² during concomitant eptifibatide and heparin therapy.⁸ ⁷² ⁸⁸ Consider possibility of heparin-induced thrombocytopenia in patients receiving concomitant heparin therapy.²⁹ ⁵⁵ ⁹³ ¹⁰⁷ ¹¹¹

If platelet count decreases to <100,000/mm³, discontinue eptifibatide and heparin and initiate appropriate treatment and monitoring.¹ Consider platelet transfusions for management of severe thrombocytopenia.⁵⁵ ⁹³ ¹⁰⁶ ¹¹¹ ¹¹²

No clinical experience with eptifibatide in patients with platelet counts <100,000/mm³.¹

Sensitivity Reactions

Hypersensitivity Reactions

Anaphylaxis reported.¹

General Precautions

Bleeding Precautions

To reduce risk of bleeding, adhere to strict anticoagulation guidelines; use a short course of low-dose, weight-adjusted heparin; avoid vascular and other trauma; carefully manage vascular (e.g., femoral artery) access site; and monitor all potential bleeding sites during and following treatment.¹ ²⁶ ²⁹ ⁴³ ⁵² ⁹⁷ ¹⁰⁷ ¹⁰⁹ Manufacturer recommends that concomitant thrombolytic therapy be used with caution.¹

In patients undergoing PCI, use caution in the placement, maintenance, and removal of vascular access sheath.¹ ²⁶ ⁴⁴ ⁵² When inserting sheath, puncture only anterior wall of femoral artery; avoid Seldinger (through and through) technique.⁸ ²⁶ ⁷² Observe appropriate precautions while sheath is in place (e.g., complete bed rest, elevation of head ≤30°, restrain limb in which sheath is inserted, frequent monitoring of vascular access site and distal pulse in the involved limb).²⁶ ²⁷ ⁷² Following PCI, consider early sheath removal (during eptifibatide IV infusion).¹ Prior to removal of sheath, discontinue heparin for 3–4 hours and allow aPTT to return to <45 seconds or ACT to <150–180 seconds.¹ ²⁶ ²⁷ ³⁵ ⁴⁴ Discontinue eptifibatide and heparin and achieve hemostasis (by applying pressure to femoral artery for at least 20–30 minutes after sheath removal²⁶ ²⁷ ) at least 2–4 hours before hospital discharge.¹ Measure and monitor hematomas for enlargement.⁸ ²⁶ ⁷²

To avoid vascular and other trauma, minimize needle punctures (e.g., arterial, IM, IV, lumbar, sub-Q, intradermal), cutdown sites, and use of nasotracheal intubation, nasogastric tubes, urinary catheters, and automatic BP cuffs²⁶ during and following treatment;¹ ⁸ ⁷² avoid establishment of IV access at noncompressible sites (e.g., subclavian or jugular veins);¹ consider using an indwelling venipuncture device (e.g., heparin lock) for drawing blood; document and monitor vascular puncture sites; and remove dressings gently and carefully.⁸ ²⁶ ⁷²

Laboratory Monitoring

Prior to administration, obtain hematocrit or hemoglobin, platelet count, S_cr, and PT or aPTT.¹ In patients undergoing PCI, also obtain ACT prior to administration.¹

In patients with unstable angina or non-ST-segment-elevation MI undergoing medical management, target aPTT between 50–70 seconds.¹

In patients undergoing PCI the manufacturer recommends targeting ACT between 200–300 seconds during PCI.¹

Monitor aPTT or ACT prior to arterial sheath removal; do not remove sheath unless aPTT ≤45 seconds or ACT <150–180 seconds.¹ ²⁶ ²⁷ ³⁵ ⁴⁴

Specific Populations

Pregnancy

Category B.¹

Lactation

Not known whether eptifibatide is distributed into milk.¹ Use with caution.¹

Pediatric Use

Safety and efficacy not established.¹ ⁸

Geriatric Use

No substantial differences in efficacy relative to younger adults.¹ However, increased incidence of bleeding complications.¹

Hepatic Impairment

Use contraindicated in patients with hepatic disease severe enough to alter synthesis of coagulation factors.⁸

Renal Impairment

Decreased clearance and increased plasma concentrations in patients with moderate to severe renal impairment (estimated Cl_cr <50 mL/minute);¹ reduced dosage recommended in such patients.¹ (See Renal Impairment under Dosage and Administration.) Use contraindicated in patients undergoing renal dialysis.¹

Common Adverse Effects

Bleeding,¹ hypotension.¹ ⁸ ⁴³

Drug Interactions

Specific Drugs

Drug	Interaction	Comments
Anticoagulants, oral	Potential increased risk of bleeding¹	Use with caution¹
Dipyridamole	Potential increased risk of bleeding¹	Use with caution¹
Enoxaparin	Pharmacokinetic or pharmacodynamic (e.g., effect on platelet aggregation) interaction unlikely¹
GP IIb/IIIa-receptor inhibitors (abciximab, tirofiban)	Possible additive pharmacologic effects¹ ⁴	Avoid concomitant use¹ ⁴
Heparin	Possible additive effects on ACT¹⁹	Reduce dosage of heparin to maintain appropriate ACT¹⁹
NSAIAs	Potential increased risk of bleeding¹	Use with caution¹
Thrombolytics (e.g., alteplase, streptokinase)	Increased risk of bleeding, including that requiring blood transfusions¹ ⁵ ³⁴	Use with caution¹ ⁴ ³⁴ ⁴³ ⁷²

Eptifibatide Pharmacokinetics

Absorption

Bioavailability

Peak plasma concentrations achieved within 5 minutes and steady-state concentrations attained within 4–6 hours following IV administration.¹ ⁴ ⁹ ⁴¹ ⁴³

Onset

Maximal inhibition of platelet aggregation occurs within 15 minutes following IV administration and is rapidly reversible.¹ ⁸ ¹²

Duration

Platelet aggregation usually returns to normal within 4–8 hours after discontinuing therapy.⁸ ¹³ ³¹ ⁴¹ ⁴³

Special Populations

Steady-state plasma concentrations double in patients with moderate to severe renal impairment (estimated Cl_cr <50 mL/minute).¹

Increased plasma concentrations in geriatric patients.¹

Distribution

Extent

Not known whether eptifibatide is distributed into breast milk.¹

Plasma Protein Binding

Approximately 25% (mainly albumin).¹ ⁸ ⁴¹ ⁴³

Elimination

Metabolism

Principally metabolized to a less active metabolite;¹ ⁹ ⁴¹ ⁷¹ 27% of dose is converted in plasma into naturally occurring amino acids.⁴ ⁴¹

Elimination Route

Eliminated by renal (40–50% of total body clearance)¹ ⁸ ⁹ ⁷¹ and nonrenal mechanisms,⁹ ⁴¹ ⁴³ ⁷¹ mainly as parent drug and metabolites.¹ In healthy men, approximately 98, 1.5, and 0.8% of a single dose was recovered in urine, feces, and breath carbon dioxide, respectively.⁹

May be removed by hemodialysis.¹

Half-life

2.5–2.8 hours in patients with CAD;¹ ⁸ ¹⁹ 0.83–2.4 hours in healthy individuals.² ⁸ ⁴² ⁷¹

Special Populations

Clearance reduced by 50% in patients with moderate to severe renal impairment (estimated Cl_cr <50 mL/minute).¹

Reduced total body clearance in geriatric patients.¹

Stability

Storage

Parenteral

Injection

2–8°C.¹ ⁸ Protect from light.¹ ⁸

May store at room temperature (15–30°C) for ≤2 months.¹ ⁸

Compatibility

Parenteral

No incompatibilities observed with IV administration sets; no compatibility studies performed with polyvinyl chloride (PVC) bags.¹

Solution Compatibility1

*Infusion may contain up to 60 mEq/L of potassium chloride.¹

Compatible
Dextrose 5% and sodium chloride 0.9%*
Sodium chloride 0.9%*

Drug Compatibility1

Admixture CompatibilityHID
Compatible
Alteplase
Amiodarone HCl
Atropine
Bivalirudin
Dobutamine HCI
Heparin sodium
Lidocaine HCI
Meperidine HCI
Metoprolol tartrate
Midazolam HCI
Morphine sulfate
Nitroglycerin
Verapamil HCI
Incompatible
Furosemide

Actions

Binds selectively to platelet GP IIb/IIIa receptors and reversibly inhibits platelet aggregation (by preventing binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa receptors).¹ ² ³ ⁴ ⁷ ⁸ ¹⁶ ³⁷ ⁷¹
Modest effect on hemostatic indices (e.g., bleeding times) and platelet function; normal hemostasis restored more rapidly than with abciximab.¹ ² ⁶ ¹⁰ ¹⁷ ⁷²
Usually does not affect PT or aPTT when administered as monotherapy.¹

Advice to Patients

Risk of serious bleeding or hemorrhage.¹
Importance of close laboratory monitoring.¹
Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses.¹
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.¹
Importance of advising patients of other important precautionary information.¹ (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Eptifibatide
Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Parenteral	Injection, for IV Use	2 mg/mL (20 mg)	Integrilin	Schering
		0.75 mg/mL (75 mg)	Integrilin	Schering

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Schering. Integrilin (eptifibatide) injection prescribing information. Kenilworth, NJ; 2007 Mar.

2. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol. 1997; 80(Suppl 4A):11b-20b. https://pubmed.ncbi.nlm.nih.gov/9291241

3. Phillips DR, Teng W, Arfsten A et al. Effect of Ca²⁺ on GP IIb-IIIa interactions with Integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 1997; 96:1488-94. https://pubmed.ncbi.nlm.nih.gov/9315536

4. Key Pharmaceuticals. Integrilin™ (eptifibatide) product monograph. Kenilworth, NJ; 1998 Aug.

5. Braunwald E, Maseri A, Armstrong PW et al. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. Eur Heart J. 1998; 19(Suppl D):D22-30. https://pubmed.ncbi.nlm.nih.gov/9597519

6. White H. Unmet therapeutic needs in the management of acute ischemia. Am J Cardiol. 1997; 80(Suppl 4A):2b-10b. https://pubmed.ncbi.nlm.nih.gov/9291240

7. Le Breton H, Plow EF, Topol EJ et al. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol. 1996; 28:1643-51. https://pubmed.ncbi.nlm.nih.gov/8962547

8. Cor Therapeutics, South San Francisco, CA, and Key Pharmaceuticals, Kenilworth, NJ: Personal communication.

9. Alton KB, Kosoglou T, Baker S et al. Disposition of¹⁴C-eptifibatide after intravenous administration to healthy men. Clin Ther. 1998; 20: 307-323. https://pubmed.ncbi.nlm.nih.gov/9589822

10. Anon. Randomised placebo-controlled trial of effect of eptifibatide on complication of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. 1997; 349:1422-8. https://pubmed.ncbi.nlm.nih.gov/9164315

11. Tcheng JE. Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Am J Cardiol. 1997; 80(Suppl 4A):21B-8B. https://pubmed.ncbi.nlm.nih.gov/9291242

12. Harrington RA, Kleiman NS, Kottke-Marchant K et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol. 1995; 76:1222-7. https://pubmed.ncbi.nlm.nih.gov/7503000

13. Ohman EM, Kleiman NS, Gacioch G et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockage with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial. Circulation. 1997; 98:846-54.

14. Moliterno DJ, Topol EJ. Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction. Thromb Haemost. 1997; 78:214-9. https://pubmed.ncbi.nlm.nih.gov/9198156

15. Harrington RA, Ohman EM, Sigmon KN et al. Intensity of inhibition of the platelet glycoprotein IIb/IIIa receptor differs among disease states. Circulation. 1995; 92(Suppl 1):488-9.

16. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol. 1996; 78(Suppl 3A):35-40. https://pubmed.ncbi.nlm.nih.gov/8751845

17. Kleiman NS. Primary and secondary safety endpoints from IMPACT II. Am J Cardiol. 1997; 80(Suppl 4A):29B-33B. https://pubmed.ncbi.nlm.nih.gov/9291243

18. Plow EF, Ginsberg MH. Molecular basis of platelet function. In: Hoffman R, Benz EJ, Shattil SJ et al, eds. Hematology. 2nd ed. Churchill Livingstone. New York, NY. 1995:1524-35.

19. Tcheng JE, Harrington RA, Kottke-Marchant K et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrilin in elective coronary intervention. Circulation. 1995; 91:2151-7. https://pubmed.ncbi.nlm.nih.gov/7697843

20. Catella-Lawson F, Fitzgerald GA. Confusion in reperfusion: problems in the clinical development of antithrombotic drugs. Circulation. 1997; 95: 793-5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037233/

21. Loscalzo J, Braunwald E. Tissue plasminogen activator. N Engl J Med. 1988; 319:925-31. https://pubmed.ncbi.nlm.nih.gov/3138537

22. Ohlstein EH, Storer B, Fujita T et al. Tissue-type plasminogen activator and streptokinase induce platelet hyperaggregability in the rabbit. Thromb Res. 1987; 46:575-85. https://pubmed.ncbi.nlm.nih.gov/3112993

23. Fitzgerald DJ, Catella F, Roy L et al. Marked platelet activation in vivo after IV streptokinase in patients with acute myocardial infarction. Circulation. 1988; 77:142-50. https://pubmed.ncbi.nlm.nih.gov/3275505

24. Gold HK, Coller BS, Yashuda T et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIbIIIa antibody in a canine preparation. Circulation. 1988; 77:670-7. https://pubmed.ncbi.nlm.nih.gov/3124974

25. Gold HK, Leinbach RC. Prevention of acute reocclusion after thrombolysis with IV recombinant tissue plasminogen activator. In: Sobel BE, Collen D, Grossbard EB, eds. Tissue plasminogen activator in thrombolytic therapy. New York: Marcel Dekker, Inc; 1987:115-30.

26. Eli Lilly and Company. ReoPro (abciximab) injection for intravenous administration prescribing information. Indianapolis, IN: 1998 Feb 12.

27. Bittl JA, Levin DC. Coronary arteriography. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. 5th ed. Philadelphia: WB Saunders Company; 1997:240-72.

28. Sanofi. Plavix (clopidogrel bisulfate) tablets prescribing information. New York, NY: 1997 Nov.

29. Merck & Co. Aggrastat (tirofiban hydrochloride) injection prescribing information. West Point, PA; 1998 May.

30. Agency for Health Care Policy and Research. Diagnosing and managing unstable angina. 1994. (AHCPR publication no. 94-0603)

31. Jennings L, Tardiff B, Scarborough R et al. Comparison of receptor occupancy and platelet aggregation response of eptifibatide administered intravenously in patients with unstable angina or non-Q-wave myocardial infarction. J Am Coll Cardiol. 1998; 31(Suppl A): 93A.

32. McClure M, Kleiman NS, Berdan LG et al. Thrombocytopenia in a large, international trial of the GP IIb/IIIa inhibitor eptifibatide in patients with acute coronary syndromes. J Am Coll Cardiol. 1998; 31(Suppl A):93A.

33. Lincoff AM, Harrington RA, Califf RM et al. Clinical efficacy of Integrilin in unstable angina is accompanied by a modest increase in hemorrhagic risk: the PURSUIT trial. J Am Coll Cardiol. 1998; 31(Suppl A):185A.

34. Ronner E, van Kesteren HAM, Zijnen P et al. Combined therapy with streptokinase and Integrilin. J Am Coll Cardiol. 1998; 31(Suppl A):191A.

35. Simko RJ, Tsung FFW, Stamek EJ et al. Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin. Ann Pharmacother. 1995; 29:1015-21. https://pubmed.ncbi.nlm.nih.gov/8845539

37. Harrington RA. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute coronary syndromes. Am J Cardiol. 1997; 80(Suppl 4A):34b-8b. https://pubmed.ncbi.nlm.nih.gov/9291244

40. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998; 339:436-43. https://pubmed.ncbi.nlm.nih.gov/9705684

41. Cor Therapeutics. Integrilin™ (eptifibatide). Summary basis of approval: clinical pharmacology/biopharmaceutics review. Reference No.: 20-718. Kenilworth, NJ. 1998.

42. Charo IF, Scarborough RM, du Mee CP et al. Pharmacodynamics of the GPIIb-IIIa antagonist integrilin: phase I clinical studies in normal healthy volunteers. Circulation. 1992; 86(Suppl I):I-260.

43. Goa KL, Noble S. Eptifibatide. A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs. 1999; 57:439-62. https://pubmed.ncbi.nlm.nih.gov/10193692

44. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994; 330:956-61. https://pubmed.ncbi.nlm.nih.gov/8121459

46. Levin T. Eptifibatide in acute coronary syndromes. N Engl J Med. 1999; 340:60. https://pubmed.ncbi.nlm.nih.gov/9882213

47. Harrington RA, Simoons ML, Topol EJ. Eptifibatide in acute coronary syndromes. N Engl J Med. 1999; 340:61. https://pubmed.ncbi.nlm.nih.gov/9882216

48. Davies MJ. The role of plaque pathology in coronary thrombosis. Clin Cardiol. 1997; 20(Suppl I):I-2-7. https://pubmed.ncbi.nlm.nih.gov/9377822

49. Topol EJ. Targeted approaches to thrombus formation: an end to the shotgun approach. Clin Cardiol. 1997; 20(Suppl I):I-22-6.

50. de Feyter PJ. The benefits and risks of coronary intervention—-balancing the equation. Clin Cardiol. 1997; 20(Suppl I):I-14-21.

51. Merlini PA, Bauer KA, Oltrona L et al. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol. 1995; 25:203-9. https://pubmed.ncbi.nlm.nih.gov/7798503

52. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995; 332:1553-9. https://pubmed.ncbi.nlm.nih.gov/7739710

53. Moll S. Eptifibatide in acute coronary syndromes. N Engl J Med. 1999; 340:60-1. https://pubmed.ncbi.nlm.nih.gov/9882215

54. Alexander JH, Harrington RA, Tuttle RH et al. Prior aspirin use predicts worse outcomes in patients with non-ST elevation acute coronary syndromes. Am J Cardiol. 1999; 83:1147-51. https://pubmed.ncbi.nlm.nih.gov/10215274

55. Lincoff AM. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. Am J Cardiol. 1998; 82:36P-42P. https://pubmed.ncbi.nlm.nih.gov/9809890

56. Alexander JH, Harrington RA. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A, and PURSUIT. Drugs. 1998; 56:965-76. https://pubmed.ncbi.nlm.nih.gov/9878986

57. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994; 308:81-106. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2539220/ https://pubmed.ncbi.nlm.nih.gov/8298418

58. Théroux P. Antiplatelet therapy: do the new platelet inhibitors add significantly to the clinical benefits of aspirin? Am Heart J. 1997; 134:S62-70.

59. Théroux P, Ouimet H, McCans J et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988; 319:1105-11. https://pubmed.ncbi.nlm.nih.gov/3050522

60. Catella-Lawson F, FitzGerald GA. Trials in myocardial infarction. Circulation. 1997; 96:3815.

61. Kleiman NS. A risk-benefit assessment of abciximab in angioplasty. Drug Saf. 1999; 20:43-57. https://pubmed.ncbi.nlm.nih.gov/9935276

62. Detre KM, Holmes DR Jr, Holubkov R et al. Incidence and consequences of periprocedural occlusion: the 1985–1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation. 1990; 82:739-50. https://pubmed.ncbi.nlm.nih.gov/2394000

63. Cairns JA, Gent M, Singer J et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med. 1985; 313:1369-75. https://pubmed.ncbi.nlm.nih.gov/3903504

64. Lewis HD, Davies JW, Archibald DG et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983; 309:396-403. https://pubmed.ncbi.nlm.nih.gov/6135989

65. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990; 336:827-30. https://pubmed.ncbi.nlm.nih.gov/1976875

66. Cohen M, Adams PC, Gareth P et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: Primary end points analysis for the ATACS trial. Circulation. 1994; 89:81-8. https://pubmed.ncbi.nlm.nih.gov/8281698

67. Oler A, Whooley MA, Oler J et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA. 1996; 276:811-5. https://pubmed.ncbi.nlm.nih.gov/8769591

68. Théroux P, Waters D, Qiu S et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation. 1993; 88(5 Pt 1):2045-8. https://pubmed.ncbi.nlm.nih.gov/8222097

69. Cairns J, Théroux P, Armstrong P et al. Unstable angina—Report from a Canadian expert round table. Can J Cardiol. 1996; 12:1279-92. https://pubmed.ncbi.nlm.nih.gov/8987969

70. Sambol NC, Tcheng JE, Kitt M et al. Population pharmacokinetics (PK) and pharmacodynamics (PD) of integrelin, a platelet aggregation inhibitor. Clin Pharmacol Ther. 1996; 59:150.

71. Anon. Eptifibatide. Drugs Future. 1998; 23:585-90.

72. Reviewers’ comments (personal observations).

73. Freedman SB, Dunn RF, Bernstein L et al. Influence of coronary collateral blood flow on the development of exertional ismchemia and Q wave infarction in patients with severe single-vessel disease. Circulation. 1985; 71:681-6. https://pubmed.ncbi.nlm.nih.gov/3971537

74. Théroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation. 1998; 97:1195-1206. https://pubmed.ncbi.nlm.nih.gov/9537346

75. Tonkin AM, Aroney CN. Guidelines for managing patients with unstable angina: rating the evidence and rationale for treatment. Med J Aust. 1997; 16:644-7.

76. Cohen M, Demers C, Gurfinkel EP et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997; 337: 447-52. https://pubmed.ncbi.nlm.nih.gov/9250846

77. Armstrong PW. Heparin in acute coronary disease-requiem for a heavyweight? N Engl J Med. 1997; 337:492-4. (IDIS 389821)

78. Swahn E, Wallentin L for the FRISC study group. Low-molecular weight heparin (fragmin) during instability in coronary artery disease (FRISC). Am J Cardiol. 1997; 80(Suppl. 5A):25E-9E. https://pubmed.ncbi.nlm.nih.gov/9296466

79. Berdan L, Weatherly BD, Widimsky P et al. Global gender variations in the care of patients with acute coronary syndromes. Circulation. 1998; 98(Suppl. 1):I-560.

80. Holmes DR, White HD, Hasdai D et al. Relationship between age and outcome in patients with acute ischemic syndromes randomized to eptifibatide or placebo: a report from the PURSUIT trial. Circulation. 1998; 98(Suppl. 1):I-359. https://pubmed.ncbi.nlm.nih.gov/9769316

81. Greenbaum AB, Hudson MP, MacAulay CM et al. Timing of events after hospitalization for acute coronary syndromes. Circulation. 1998; 98(Suppl. 1):I-630.

82. Berdan LG, Kleiman NS, Guerci A et al. Unstable angina in the US: patients and management. Circulation. 1998; 98(Suppl. 1):I-359.

83. Gilchrist IC, Thel MC, Joseph D et al. Enhanced platelet Iib/IIIa inhibition with eptifibatide via high-dose, double-bolus dosing: final results of the PRIDE study. Circulation. 1998; 98(Suppl.1):I-844-5.

84. Akkerhuis M, Boersma E, Harrington RA et al. Eptifibatide protects against adverse cardiac complications both before and during percutaneous intervention in patients with acute coronary syndromes without Stelevation. J Am Coll Cardiol. 1999; 33(Suppl. A):40A.

85. Rao AK, Pratt C, Berke A et al. Thrombolysis in myocardial infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988; 11:1-11. https://pubmed.ncbi.nlm.nih.gov/3121710

86. Vorchheimer DA, Guzman IC, Greenberg S et al. Safety and efficacy of eptifibatide therapy in patients with previous stroke or transient ischemic attack. J Am Coll Cardiol. 1999; 33(Suppl. A):330A.

87. Mahaffey KW, Harrington RA, Simoons ML et al. Stroke in patients with acute coronary syndromes: incidence and outcomes in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. Circulation. 1999; 99:2371-7. https://pubmed.ncbi.nlm.nih.gov/10318656

88. Wyeth-Ayerst Laboratories. Heparin sodium injection prescribing information. In: Physicians’ desk reference. 53rd ed. Montvale, NJ: Medical Economics Company Inc; 1999:3305-7.

89. The EPILOG Investigators. Platelet glycoprotein Iib/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997; 336:1689-96. https://pubmed.ncbi.nlm.nih.gov/9182212

90. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 1996; 347:561-8. https://pubmed.ncbi.nlm.nih.gov/8596317

91. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists: what are the relevant issues concerning their pharmacology and clinical use? Circulation. 1999; 100:437-44.

92. Kleiman NS, Lincoff AM, Ohman EM et al. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings. Am Heart J. 1998; 136:532-42.

93. Madan M, Berkowitz SD, Tcheng JE. Glycoprotein IIb/IIIa integrin blockade. Circulation. 1998; 98:2629-35. https://pubmed.ncbi.nlm.nih.gov/9843473

94. Zaacks SM, Liebson PR, Calvin JE et al. Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications? J Am Coll Cardiol. 1999; 33:107-18.

95. Chesebro JH, Badimon JJ. Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease. N Engl J Med. 1998; 338:1539-41. https://pubmed.ncbi.nlm.nih.gov/9593795

96. Kong DF, Califf Rm, Miller DP et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ishemic heart disease. Circulation. 1998; 98:2829-35. https://pubmed.ncbi.nlm.nih.gov/9860783

97. Reviewers’ comments (personal observations) on tirofiban.

98. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998; 338:1488-97. https://pubmed.ncbi.nlm.nih.gov/9599103

99. Vorchheimer DA, Badimon JJ, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA. 1999; 281:1407-14. https://pubmed.ncbi.nlm.nih.gov/10217057

100. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997; 96:1445-53. https://pubmed.ncbi.nlm.nih.gov/9315530

101. Gibson CM, Goel M, Cohen DJ et al. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. J Am Coll Cardiol. 1998; 32:28-34. https://pubmed.ncbi.nlm.nih.gov/9669245

102. Dobesh PP, Latham KA. Advancing the battle against ischemic syndromes: a focus on the GP-IIb/IIIa inhibitors. Pharmacotherapy. 1998; 18:663-85. https://pubmed.ncbi.nlm.nih.gov/9692642

104. Antman EM, Fox KM for the International Cardiology Forum. Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. Am Heart J. 2000; 139:461-75. https://pubmed.ncbi.nlm.nih.gov/10689261

105. Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? J Am Coll Cardiol. 2000; 35:1699-702.

106. Quinn M, Fitzgerald DJ. Long-term administration of glycoprotein IIb/IIIa antagonists. Am Heart J. 1998; 135:S113-8. https://pubmed.ncbi.nlm.nih.gov/9588390

107. Merck & Co. Product information form for American hospital formulary service: Aggrastat (tirofiban hydrochloride). West Point, PA; 1998.

108. Armstrong PW. Pursuing progress in acute coronary syndromes. Circulation. 1999; 100:1586-9. https://pubmed.ncbi.nlm.nih.gov/10517727

109. Merck & Co., West Point, PA: Personal communication on tirofiban.

110. Giugliano RP, Hyatt RR. Thrombocytopenia with GP IIb/IIIa inhibitors: a meta-analysis. J Am Coll Cardiol. 1998; 31(Suppl 2A):185A.

111. Ferguson JJ, Kereiakes DJ, Adgey AAJ et al. Safe use of platelet GP IIb/IIIa inhibitors. Am Heart J. 1998; 135:S77-89.

112. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb/IIIa blockers. Lancet. 1999; 353:227-31. https://pubmed.ncbi.nlm.nih.gov/9923894

113. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol. 2000; 36:970-1062. https://pubmed.ncbi.nlm.nih.gov/10987629

117. Enhanced Suppression of the Platelet IIb/IIIa receptor with Integrelin Therapy (ESPRIT) Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2001; 356:2037-44.

118. O’Shea JC, Hafley GE, Greenberg S et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA. 2001; 285:2468-73. https://pubmed.ncbi.nlm.nih.gov/11368699

124. Goodman S. Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-segement-elevation acute coronary syndrome: insights for the INTERACT trial. Am Heart J. 2005; 149:S73-80. https://pubmed.ncbi.nlm.nih.gov/16124951

125. James S, Armstrong P, Califf R et al. Safety and efficacy of abciximab combined with dalteparin in the treatment of acute coronary syndromes. Eur Heart J. 2002; 23:1538-45. https://pubmed.ncbi.nlm.nih.gov/12242074

126. Goodman SG, Fitchett D, Armstrong P et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfarctionated heparin in high-risk patients with non-ST-sgement elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation. 2003; 107:238-44. https://pubmed.ncbi.nlm.nih.gov/12538422

128. Lansky AJ, Hochman JS, Ward PA et al. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professional from the American Heart Association. Circulation. 2005; 111:940-3. https://pubmed.ncbi.nlm.nih.gov/15687113

132. Antman EM, Hand M, Armstrong PW et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. J Am Coll Cardiol. 2008; 51:210-47. https://pubmed.ncbi.nlm.nih.gov/18191746

991. Wright RS, Anderson JL, Adams CD et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2011; 57:e215-367.

994. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011; 58:e44-122. https://pubmed.ncbi.nlm.nih.gov/22070834

995. Hamm CW, Bassand JP, Agewall S et al, for The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST -segment elevation of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2011; 32:2999-3054. https://pubmed.ncbi.nlm.nih.gov/21873419

1016. Eikelboom JW, Hirsh J, Spencer FA et al. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e89S-119S.

1100. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 130:e344-426. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676081/

HID. Trissel LA. Handbook on injectable drugs. 14th ed; Bethesda, MD: American Society of Health-System Pharmacists; 2007:631.

More about eptifibatide

Patient resources

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

User Reviews & Ratings

Review this drug